Healthcare staff are the group with the very best threat of COVID-19 transmission. The sickness of healthcare staff poses a threat to sufferers admitted to the hospital, colleagues and households in addition to their very own well being. On this examine, it was aimed to find out the chance evaluation and the elements related to threat standing of an college hospital healthcare staff after dangerous COVID-19 contact. The info of the descriptive examine have been obtained from 773 follow-up information of 555 healthcare staff who utilized with COVID-19 dangerous contact between 06.04-10.05.2020. With the bodily enchancment of the remaining areas of the staff and the association of the breaks, the dangerous contact between colleagues within the social areas shall be lowered.
Workers who have been optimistic for RT-PCR evaluated as “sufferers” and others as “dangerous contact”. Danger evaluation was labeled as no threat, low, medium and excessive threat contact in keeping with the “Algorithm of Evaluation of Well being Employees with COVID-19 Contact” of the Ministry of Well being. The connection between the chance ranges of the individuals and their demographic and office traits and their utilization of non-public safety have been evaluated. Imply, normal deviation, share, chi-square and ANOVA checks have been used within the evaluation of the information. The common age of the healthcare staff was decided as 34.4 ± 7.6 years. It was decided that 56.2% of those that had contact have been feminine, 62.9% have been married and 17.5% had a further illness.
It was decided that 45.6% of the dangerous contacts have been nurses, 18.4% have been supportive personnel and 16.9% have been medical doctors. Whereas 46.5% of the contacts have been discovered as medium, 28.0% low, 17.1% excessive threat and eight.4% threat free. 38.2% of dangerous contacts occurred whereas working in inner/surgical clinics. Whereas 66.0% of the staff had dangerous contact throughout affected person care and therapy, 25% had dangerous contact with colleagues in social settings. Excessive-risk contact was larger in social relations between workers. The supply of the contact was a colleague in 73.2% of the staff.
The common age of high-risk workers was smaller than these of low-risk. Whereas 54.5% of the staff wore surgical masks throughout contact, 67.8% of the sufferers didn’t have a masks. Of 555 workers adopted, 37 (6.7%) have been recognized as COVID-19; 48.6% of the sufferers have been nurses and 18.9% have been medical doctors. It was decided that 48.6% of the healthcare staff have been working within the COVID-19 service, outpatient clinic or intensive care unit on the time of analysis. The supply of the an infection was regarded as a colleague in 51.6% of the sufferers. COVID-19 was extra widespread in nurses and medical doctors.
It was decided that dangerous contact additionally occurred in companies apart from the models the place COVID-19 sufferers have been handled and dangerous contact usually passed off whereas offering healthcare to the sufferers and through social relations between the staff. Unprotected contact of the staff with one another within the office was recognized as an essential threat supply. Insufficient use of non-public protecting tools by healthcare staff led to a rise in medium and excessive threat contacts. The usage of masks by sufferers and their family members in the course of the well being service supply and the correct use of non-public protecting tools by healthcare professionals will scale back the chance.
Challenges for bronchial asthma models in response to COVID-19: a qualitative group dynamics evaluation
To develop a set of suggestions for the administration of extreme bronchial asthma throughout COVID-19 pandemic. Eleven pneumologists and allergologists who have been employees members of formally accredited bronchial asthma models in Catalonia (Spain) participated in a cross-section examine primarily based on three 2-hour digital workshops (first: brainstorming, second: identification of impacts and challenges summarized in 10 matters, third: institution of ultimate suggestions by consensus).
Impacts and challenges recognized have been enchancment of referral protocols between completely different ranges of care; evaluation of the minimal variety of perform checks to be carried out and promote the efficiency of spirometry in major care; implementation of videoconferencing, cellular apps, phone calls, or integral digital platforms for the follow-up of sufferers, and definition of the mannequin of care (face-to-face, telematics, combined) in keeping with the affected person’s particular person wants; self-administration of biologics for domiciliary therapy; and empowerment of the position of nursing and hospital pharmacy specifically for follow-up and self-administration of biologics.
13 mm Diameter Solid Titanium Tip |
0-120-0011 |
Biologics |
13 mm |
EUR 533 |
19 mm Diameter Tapped Titanium Tip |
0-120-0012 |
Biologics |
19 mm |
EUR 639 |
19 mm Diameter Solid Titanium Tip |
0-120-0013 |
Biologics |
19 mm |
EUR 570 |
25 mm Diameter Tapped Titanium Tip |
0-120-0014 |
Biologics |
25 mm |
EUR 682 |
25 mm Diameter Solid Titanium Tip |
0-120-0015 |
Biologics |
25 mm |
EUR 614 |
Flat Replaceable Tips 13 mm Diameter Flat Titanium Tip |
0-120-0016 |
Biologics |
13 mm |
EUR 86 |
Description: use with corresponding Tapped Tips and Tapped Extender Tips |
Flat Replaceable Tips 19 mm Diameter Flat Titanium Tip |
0-120-0017 |
Biologics |
19 mm |
EUR 92 |
Description: use with corresponding Tapped Tips and Tapped Extender Tips |
Flat Replaceable Tips 25 mm Diameter Flat Titanium Tip |
0-120-0018 |
Biologics |
25 mm |
EUR 100 |
Description: use with corresponding Tapped Tips and Tapped Extender Tips |
Titanium Cup Tip, 250 ml |
0-120-0019 |
Biologics |
250 ml |
EUR 1377 |
Description: includes Interface Washers |
Microtube Tray, 8 Position (for 250 ml Cup Tip) |
0-120-0021 |
Biologics |
each |
EUR 113 |
Description: includes Interface Washers |
Continuous Flow Chamber |
0-120-0026 |
Biologics |
each |
EUR 774 |
Description: includes Interface Washers |
Interface Washers 1.5” Diameter, 5/Pkg |
0-120-003 |
Biologics |
1.5'' Diameter |
EUR 31 |
13 mm Diameter Solid Titanium Extender Tip |
0-120-0032 |
Biologics |
13 mm |
EUR 301 |
13 mm Diameter Tapped Titanium Extender Tip |
0-120-0033 |
Biologics |
13 mm |
EUR 362 |
19 mm Diameter Solid Titanium Extender Tip |
0-120-0034 |
Biologics |
19 mm |
EUR 315 |
19 mm Diameter Tapped Titanium Extender Tip |
0-120-0035 |
Biologics |
19 mm |
EUR 375 |
25 mm Diameter Solid Titanium Extender Tip |
0-120-0036 |
Biologics |
25 mm |
EUR 328 |
25 mm Diameter Tapped Titanium Extender Tip |
0-120-0037 |
Biologics |
25 mm |
EUR 389 |
KoldPod, 1.5ml Micro Tube |
0-120-0038 |
Biologics |
1.5 ml |
EUR 152 |
Description: Thermo conductive tube pods |
KoldPod, 15ml Conical Tube |
0-120-0039 |
Biologics |
15 ml |
EUR 275 |
Description: Thermo conductive tube pods |
KoldPod, 50ml Conical Tube |
0-120-0040 |
Biologics |
50 ml |
EUR 290 |
Description: Thermo conductive tube pods |
Model 150 V/T Ultrasonic Homogenizer |
0-121-0002 |
Biologics |
210-240V/50-60Hz |
EUR 2920 |
|
Description: Delivers up to 150 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample processing processing. |
Model 300 V/T Ultrasonic Homogenizer |
0-122-0002 |
Biologics |
210-240V/50-60Hz |
EUR 3520 |
|
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample. |
SONABOZ Sound Abating Chamber |
0-125-0001 |
Biologics |
each |
EUR 1020 |
Description: Reduces cavitational sound emitted during processing. |
Model 3000 Ultrasonic Homogenizer |
0-127-0002 |
Biologics |
210-240V/50-60Hz |
EUR 4120 |
|
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip and includes an intergrated Sound Abating Chmaber to reduce cavitational sound emitted during processing. The Timer and Duty Cycle function increase preciosion in sample. |
Model 3000MP Ultrasonic Homogenizer |
0-128-0002 |
Biologics |
210-240V/50-60Hz |
EUR 4720 |
|
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip with preciosion control from a microprocessor and a graphical user interface displayed on a large (145 mm) LCD display. The integrated Sound Abating Chamber reduces cavitational sound emitted during processing. |
OMNICON® Zone Reader, 210-240V/50-60Hz |
0-131-0002 |
Biologics |
210-240V/50-60Hz |
EUR 35200 |
|
Description: Designed to Perform multi-plate Assays on round 90/100mm Petri Dishes. The integrated LED illumination system provides transmitted light for brightfield and darkfield illumination of transparent media. |
OMNI-Noculator Peni Cylinder Filler, 210-240V/50-60Hz |
0-134-0002 |
Biologics |
210-240V/50-60Hz |
EUR 32200 |
|
Description: A robotic liquid handling system designed to dispense Peni Cylinders and fill Peni Cylinders with the corresponding antibiotic liquid sample. |
Peni Cylinder Dispenser with Manual Hopper |
0-144-0002 |
Biologics |
each |
EUR 5406 |
|
Description: Dispenser can be configured to dispense 4 or 6 Peni Cylinders onto a petri dish. |
Peni Cylinder Dispenser with Motorized Hopper, 100-240V/50-60Hz |
0-144-0003 |
Biologics |
100-240V/50-60Hz |
EUR 6254 |
Description: The motorized hopper can be configured to dispense 4 or 6 Peni Cylinders onto a petri Dispenser can be disassembled for disinfection. |
Stainless Steel Peni Cylinder with Flat Face |
0-144-0005 |
Biologics |
6mm I.D. x 8mm O.D. x 10mm Long |
EUR 399 |
Description: sold in packages of 100 pieces |
Stainless Steel Peni Cylinder with Chamfered Face |
0-144-0006 |
Biologics |
6mm I.D. x 8mm O.D. x 10mm Long |
EUR 412 |
Description: sold in packages of 100 pieces |
Custom development of ELISAs for other species or antibody isotypes not listed in the catalog. Custom testing of samples for IgG/IgM/IgA or total (IgG+IgM+IgA) |
000-CUS |
Alpha Diagnostics |
Custom |
EUR 602 |
Alpha-Bungarotoxin, CF®405S, 500 ug |
00002 |
Biotium |
1UG |
EUR 527 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-bungarotoxin, CF405s |
00002 |
Cusabio |
500uG |
EUR 594 |
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-Bungarotoxin, CF®405S, 500 ug |
00002-1 |
Biotium |
EA |
EUR 527 |
Alpha-Bungarotoxin, CF®405S 100ug |
00002-100ug |
Biotium |
100uG |
EUR 132 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®680R, 500 ug |
9-00003 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®680R, 500 ug |
00003-1 |
Biotium |
EA |
EUR 527 |
Alpha-Bungarotoxin, CF®680R 100ug |
9-00003 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®640R, 500 ug |
9-00004 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®640R, 500 ug |
00004-1 |
Biotium |
EA |
EUR 527 |
Alpha-Bungarotoxin, CF®640R 100ug |
9-00004 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®488A, 500 ug |
9-00005 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®488A, 500 ug |
00005-1 |
Biotium |
EA |
EUR 527 |
Alpha-Bungarotoxin CF®488A 100ug |
9-00005 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®568, 500 ug |
9-00006 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®568, 500 ug |
00006-1 |
Biotium |
EA |
EUR 527 |
Alpha-Bungarotoxin, CF®568 100ug |
9-00006 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®594, 500 ug |
9-00007 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®594, 500 ug |
00007-1 |
Biotium |
EA |
EUR 527 |
Alpha-Bungarotoxin CF®594 100ug |
9-00007 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®633, 500 ug |
9-00009 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®633, 500 ug |
00009-1 |
Biotium |
EA |
EUR 527 |
Alpha-Bungarotoxin, CF®633 100ug |
9-00009 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
SARS-CoV-2 Indicator Cell Line for RNA Replication - GFP Reporter only |
0001-PP-001 |
IBT Bioservices |
1 cell line (can order x amount) |
EUR 12000 |
Description: SARS-CoV-2 GFP reporter cell line using HEK293T (ACE2/TMPRSS2) cells |
Alpha-Bungarotoxin, 1 mg |
00010-1 |
Biotium |
1MG |
EUR 193 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, 1 mg |
00010-1-1 |
Biotium |
EA |
EUR 193 |
Fluorescein-Alpha-Bungarotoxin, 500 ug |
00011 |
Biotium |
500uG |
EUR 376 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Fluorescein-Alpha-Bungarotoxin, 500 ug |
00011-1 |
Biotium |
EA |
EUR 376 |
Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug |
00012 |
Biotium |
500uG |
EUR 394 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug |
00012-1 |
Biotium |
EA |
EUR 394 |
Fluorescein-alpha-bungarotoxin, 10x50ug |
00013 |
Biotium |
10ST |
EUR 436 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Fluorescein-alpha-bungarotoxin, 10x50ug |
00013-1 |
Biotium |
EA |
EUR 436 |
Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug |
00014 |
Biotium |
10ST |
EUR 494 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug |
00014-1 |
Biotium |
EA |
EUR 494 |
Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug |
00015 |
Biotium |
500uG |
EUR 494 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug |
00015-1 |
Biotium |
EA |
EUR 494 |
Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug |
00016 |
Biotium |
10ST |
EUR 560 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug |
00016-1 |
Biotium |
EA |
EUR 560 |
Biotin-XX-A-Bungarotoxin, 500 ug |
00017 |
Biotium |
500uG |
EUR 455 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Biotin-XX-A-Bungarotoxin, 500 ug |
00017-1 |
Biotium |
EA |
EUR 455 |
Alpha-Bungarotoxin, CF®555, 500 ug |
9-00018 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®555, 500 ug |
00018-1 |
Biotium |
EA |
EUR 527 |
Alpha-Bungarotoxin, CF®555 100ug |
9-00018 |
Biotium |
-
Ask for price
-
Ask for price
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Biotin-cAMP, 1 mg |
00020 |
Biotium |
1MG |
EUR 298 |
|
Description: N/A |
Biotin-cAMP, 1 mg |
00020-1 |
Biotium |
20ST |
EUR 298 |
|
Description: N/A |
Biotin-cAMP, 50 ug |
00020-1-1 |
Biotium |
EA |
EUR 414 |
Biotin-cGMP, 1 mg |
00021 |
Biotium |
1MG |
EUR 331 |
|
Description: N/A |
Biotin-cGMP, 1 mg |
00021-1 |
Biotium |
20ST |
EUR 331 |
|
Description: N/A |
Biotin-cGMP, 20x50 ug |
00021-1-1 |
Biotium |
EA |
EUR 447 |
Cyanine 644-cAMP, 1 mg |
00022 |
Biotium |
1MG |
EUR 496 |
|
Description: N/A |
Cyanine 644-cAMP, 1 mg |
00022-1 |
Biotium |
20ST |
EUR 496 |
|
Description: N/A |
Cyanine 644-cAMP, 20x50 ug |
00022-1-1 |
Biotium |
EA |
EUR 647 |
Fluorescein Methotrexate, Triammonium Salt, 1 mg |
00023 |
Biotium |
1MG |
EUR 285 |
|
Description: N/A |
Fluorescein Methotrexate, Triammonium Salt, 1 mg |
00023-1 |
Biotium |
EA |
EUR 285 |
Staurosporine |
00025 |
Biotium |
100uG |
EUR 100 |
|
Description: N/A |
Staurosporine |
00025-1 |
Biotium |
EA |
EUR 100 |
Alpha-Bungarotoxin, CF®543, 500 ug |
00026 |
Biotium |
500uG |
EUR 527 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Alpha-Bungarotoxin, CF®543, 500 ug |
00026-1 |
Biotium |
EA |
EUR 527 |
Alpha-Bungarotoxin, CF®543, 100 ug |
00026-100ug |
Biotium |
1UG |
EUR 132 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
Rhodamine Phalloidin 300U |
00027 |
Biotium |
300 |
EUR 364 |
|
Description: N/A |
Rhodamine Phalloidin 300U |
00027-1 |
Biotium |
EA |
EUR 364 |
Biotin-XX-Phalloidin |
00028 |
Biotium |
100U |
EUR 466 |
|
Description: N/A |
Biotin-XX-Phalloidin |
00028-1 |
Biotium |
EA |
EUR 466 |
Fluorescein-Phalloidin |
00030 |
Biotium |
300U |
EUR 364 |
|
Description: N/A |
Fluorescein-Phalloidin |
00030-1 |
Biotium |
EA |
EUR 364 |
Rhodamine 110 Phalloidin |
00032 |
Biotium |
300ST |
EUR 364 |
|
Description: N/A |
Rhodamine 110 Phalloidin |
00032-1 |
Biotium |
EA |
EUR 364 |
Sulforhodamine 101 (Texas Red®) Phalloidin |
00033 |
Biotium |
300EU |
EUR 364 |
|
Description: N/A |
Sulforhodamine 101 (Texas Red®) Phalloidin |
00033-1 |
Biotium |
EA |
EUR 364 |
Phalloidin, CF®405M |
00034 |
Biotium |
300U |
EUR 482 |
|
Description: N/A |
Phalloidin, CF®405M |
00034-1 |
Biotium |
EA |
EUR 482 |
Phalloidin, CF®405M |
00034-T |
Biotium |
50U |
EUR 101 |
|
Description: N/A |
Phalloidin, CF®405M |
00034-T-1 |
Biotium |
EA |
EUR 101 |
CF®488A-cAMP |
00036 |
Biotium |
100ug |
EUR 136 |
|
Description: N/A |
CF®488A-cAMP |
00036-1 |
Biotium |
EA |
EUR 136 |
CF®640R-cAMP |
00037 |
Biotium |
100ug |
EUR 136 |
|
Description: N/A |
CF®640R-cAMP |
00037-1 |
Biotium |
EA |
EUR 136 |
Phalloidin, CF555 |
00040 |
Biotium |
300U |
EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF555 |
00040-T |
Biotium |
50U |
EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF®647, 300 U |
00041 |
Biotium |
300U |
EUR 482 |
|
Description: N/A |
Phalloidin, CF®647, 300 U |
00041-1 |
Biotium |
EA |
EUR 482 |
Phalloidin, CF®647, 50 U |
00041-T |
Biotium |
50U |
EUR 101 |
|
Description: N/A |
Phalloidin, CF®647, 50 U |
00041-T-1 |
Biotium |
EA |
EUR 101 |
Phalloidin, CF®488A, 300 U |
00042 |
Biotium |
300U |
EUR 482 |
|
Description: N/A |
Phalloidin, CF®488A, 300 U |
00042-1 |
Biotium |
EA |
EUR 482 |
Phalloidin, CF®488A, 50 U |
00042-T |
Biotium |
50U |
EUR 101 |
|
Description: N/A |
Phalloidin, CF®488A, 50 U |
00042-T-1 |
Biotium |
EA |
EUR 101 |
Phalloidin, CF®543, 300 U |
00043 |
Biotium |
300U |
EUR 482 |
|
Description: N/A |
Phalloidin, CF®543, 300 U |
00043-1 |
Biotium |
EA |
EUR 482 |
Phalloidin, CF®543, 50 U |
00043-T |
Biotium |
50U |
EUR 101 |
|
Description: N/A |
Phalloidin, CF®543, 50 U |
00043-T-1 |
Biotium |
EA |
EUR 101 |
Phalloidin, CF®568, 300 U |
00044 |
Biotium |
300U |
EUR 482 |
|
Description: N/A |
Phalloidin, CF®568, 300 U |
00044-1 |
Biotium |
EA |
EUR 482 |
Phalloidin, CF®568, 50 U |
00044-T |
Biotium |
50U |
EUR 101 |
|
Description: N/A |
Phalloidin, CF®568, 50 U |
00044-T-1 |
Biotium |
EA |
EUR 101 |
Phalloidin, CF®594, 300 U |
00045 |
Biotium |
300U |
EUR 482 |
|
Description: N/A |
Phalloidin, CF®594, 300 U |
00045-1 |
Biotium |
EA |
EUR 482 |
Phalloidin, CF®594, 50 U |
00045-T |
Biotium |
50U |
EUR 101 |
|
Description: N/A |
Phalloidin, CF®594, 50 U |
00045-T-1 |
Biotium |
EA |
EUR 101 |
Phalloidin, CF®633, 300 U |
00046 |
Biotium |
300U |
EUR 482 |
|
Description: N/A |
Phalloidin, CF®633, 300 U |
00046-1 |
Biotium |
EA |
EUR 482 |
Phalloidin, CF®633, 50 U |
00046-T |
Biotium |
50U |
EUR 101 |
|
Description: N/A |
Phalloidin, CF®633, 50 U |
00046-T-1 |
Biotium |
EA |
EUR 101 |
Phalloidin, CF®660R, 300 U |
00047 |
Biotium |
300U |
EUR 482 |
|
Description: N/A |
Phalloidin, CF®660R, 300 U |
00047-1 |
Biotium |
EA |
EUR 482 |
Phalloidin, CF®660R, 50 U |
00047-T |
Biotium |
50U |
EUR 101 |
|
Description: N/A |
Phalloidin, CF®660R, 50 U |
00047-T-1 |
Biotium |
EA |
EUR 101 |
Phalloidin, CF®680R, 300 U |
00048 |
Biotium |
300U |
EUR 513 |
|
Description: N/A |
The primary suggestions included coordination between major care and specialised care session, optimization of lung perform testing, implementation of telemedicine, and the position of nursing and hospital pharmacy. The precise proposals in response to the impact of COVID-19 pandemic centered on 4 areas of curiosity (coordination between major care and specialised care, optimization of lung perform testing, implementation of telemedicine, and empowerment of the position of nursing and hospital pharmacy) could also be generalized to different well being care settings, and assist to introduce new methods of caring bronchial asthma sufferers within the COVID-19 context.
Neighborhood-led HIV self-testing for males who’ve intercourse with males in Lebanon: classes discovered and influence of COVID-19
The NAP performed a collection of workshops (July-November 2018) to introduce HIVST companies for healthcare staff working at completely different NGOs. The workshops highlighted that HIVST could be distributed free of charge, that it will be confidential and voluntary, and that individuals have been inspired to inform the NGOs of their outcomes, which might be saved strictly confidential. NGOs collected knowledge anonymously and confidentially from beneficiaries (age, consistency of condom use and HIV testing historical past), who have been requested to name again with the outcomes of their HIVST. On the NAP, knowledge have been mixed, aggregated and analysed.